China News Service, Beijing, November 8 (Reporter Du Yan) The Beijing Municipal Medical Security Bureau said today that since 2019, Beijing has completed the implementation of six batches of state-organized drug centralized procurement results, and the seventh batch of state-organized drug centralized procurement has been implemented. The results of the selected selection are expected to be implemented in Beijing in November. The national centralized procurement of drugs has reached 294, covering common and chronic diseases such as hypertension, coronary heart disease and diabetes, as well as drugs for major diseases such as lung cancer and breast cancer. More than 50%, the average completion rate of the agreed tasks reached 150%, and the cumulative cost of drugs was reduced by 7.5 billion yuan.

  The state's organization of the centralized procurement and use of pharmaceutical consumables is a political task for comprehensively deepening the reform, and it is also a comprehensive, systematic and innovative reform task, which is of great significance for further promoting the reform of the medical and health system.

Through in-depth promotion of centralized and volume-based procurement, the price of medicines will continue to be lowered and more patients will benefit. This is not only a major reform for the country to force the high-quality development of China's pharmaceutical industry, but also a key measure to solve the problem of "expensive medical treatment".

Continuing efforts to help the sick and the weak, the people's sense of gain, happiness, and security will become more fulfilling and secure.

The market share of selected drugs with high-quality curative effect has increased significantly

  Starting from the first batch of national centralized procurement pilots in 2019, with high-quality curative drugs such as original research drugs as reference, only drugs that have passed the quality and efficacy consistency evaluation of the national drug administration department are eligible to participate in the centralized procurement selection. Other generic drugs produced and supplied with low standards have been suspended from online purchases, the market share of high-quality curative drugs has been greatly increased, and the quality of medicines for the common people has generally improved.

  On the occasion of the implementation of the country's first batch of centralized procurement pilots, a prospective organization in Beijing carried out a real-world study on the clinical efficacy and safety of selected drugs. Among them, the selected generic drug is equivalent to the original research drug in terms of clinical efficacy and use, and there is no statistical difference in adverse reactions.

Reduce the cost of surgical consumables and save an estimated 400 million yuan a year

  In January 2021, after the results of the centralized procurement of coronary stents by the national organization were implemented, the average price of the selected coronary stents dropped from an average of 13,000 yuan to an average of 700 yuan, an average decrease of 93%, which saved Beijing 800 million in procurement costs. Yuan.

The results of the centralized procurement of artificial joints organized by the state implemented in April this year have an average drop of 82%, and an estimated cost savings of 400 million yuan a year. Among them, the average price of primary hip replacement has dropped from 35,000 yuan to about 7,000 yuan; primary replacement The average price of knee joints dropped from 32,000 yuan to around 5,000 yuan.

Large-scale public medical institutions in Beijing have actively participated, and signed contracts to purchase nearly 100,000 coronary stents and nearly 27,000 sets of artificial joints, which greatly reduced the public's medical burden.

Formulate supporting policies and measures for "one drop, one liter and one translation"

  Taking the results of centralized procurement of coronary stents by national organizations in Beijing as an example, Beijing has formulated supporting policies and measures of "one drop, one liter and one translation" to achieve multiple benefits.

"One drop" means that the purchase price of selected coronary stents has been greatly reduced through volume procurement, from an average of 13,000 yuan to an average of 700 yuan, and the full amount is included in the scope of medical insurance reimbursement, which significantly reduces the cost of surgical consumables for the masses.

"One liter" means that according to the spirit of the national guidance, referring to the current price level of coronary stent implantation in surrounding provinces, the operation price should be moderately increased, so as to further reflect the value of medical personnel and mobilize the enthusiasm of medical personnel.

"One translation" refers to the promotion and implementation of the DRG payment reform for coronary stent implantation disease groups in the city, and the translation of the original cost of the medical insurance fund for purchasing stent consumables into the cost of purchasing hospital medical services.

Innovate the local centralized procurement model and continue to expand the effectiveness of centralized procurement

  According to the unified national deployment, according to the overall situation of supply and demand in the drug market, combined with clinical reality and patient needs, Beijing took the lead in establishing volume-based linkage, volume-based negotiation, and order-based procurement of shortage drugs on the basis of the national centralized procurement and volume-based bidding model. Various new modes of centralized procurement with volume not only expand the scope of drugs from generic drugs and original drugs that have passed the consistency evaluation to drugs that have not passed the consistency evaluation, but also include exclusive drugs and shortage drugs with insufficient competition. Procurement Scope.

Carry out centralized collection of 38 chemicals and 84 proprietary Chinese medicines

  In terms of drug categories, it has also achieved full coverage of the three major drug fields from chemicals, biological products, to Chinese patent medicines.

  At present, Beijing has organized the mass collection of 38 chemical drugs and 84 Chinese patent medicines, covering common diseases, chronic diseases and clinical shortage drugs. Except for the 9 drugs that have been implemented, the selection results of the remaining drugs will be all It will be implemented before the end of the year.

By then, the price of medicines in Beijing will be further reduced, and the average drop is expected to exceed 40%, and the annual cost of medicines will be reduced by 1 billion yuan.

"One product, one policy" has implemented the results of the selection of 5 types of medical consumables

  For a long time, the use system of high-value medical consumables has been complicated, and doctors in each hospital have strong brand awareness of surgical consumables.

  The centralized procurement of consumables in Beijing adheres to the principle of one product, one policy, and designs the procurement plan in a targeted manner, demand-oriented, result-oriented, and tailor-made suitable centralized procurement rules.

To avoid shortage of some necessary components due to unsuccessful bids, and to avoid price increases for some components due to not being included in centralized procurement, to ensure the integrity and safety of clinical treatment.

  As of October, Beijing took the lead in organizing and participating in the completion of the Beijing-Tianjin-Hebei "3+N" pacemaker (down 50%), coronary drug balloon (down 71%), intraocular lens (down 54%), coronary artery The procurement of 5 types of medical consumables for dilation balloons (90% drop) and staplers (88% drop) has been carried out and the selection results have been implemented.

At present, it is organizing the centralized procurement of orthopaedic trauma consumables with volume, and sharing the results of the selection of orthopedic trauma consumables in brother provinces through volume linkage. Through expert negotiation, the purchase price of commonly used orthopedic trauma consumables in Beijing is further reduced, and the selected results are expected to be produced within this year.

(Finish)